XORTX Therapeutics (XRTX) Income from Non-Controlling Interests (2021 - 2026)
XORTX Therapeutics (XRTX) posted Income from Non-Controlling Interests of $7000.0 for Q1 2026, down 92.47% on a QoQ basis from $93000.0 in Q4 2025, and down 97.15% year-over-year from $246000.0 in Q1 2025.
XORTX Therapeutics (XRTX) Income from Non-Controlling Interests (2021 - 2026) Analysis & Trends
XORTX Therapeutics' Income from Non-Controlling Interests history runs 6 years deep, the most recent figure standing at $7000.0 for Q1 2026.
- Quarterly Income from Non-Controlling Interests fell 97.15% year-over-year to $7000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$541700.0 (down 135.4% YoY) and the FY2025 annual result came in at $564000.0, down 45.51% from the prior year.
- Income from Non-Controlling Interests was $7000.0 for Q1 2026 at XORTX Therapeutics, down from $93000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $8.5 million in Q4 2023 and bottomed at -$1.8 million in Q1 2023.
- A 5-year average of $370774.3 and a median of $170066.0 in 2024 frame the typical range for Income from Non-Controlling Interests.
- Peak annual rise in Income from Non-Controlling Interests reached 437.88% in 2023, while the deepest fall reached 662.99% in 2023.
- XORTX Therapeutics' Income from Non-Controlling Interests stood at $1.6 million in 2022, then jumped by 437.88% to $8.5 million in 2023, then tumbled by 89.76% to $870349.0 in 2024, then plunged by 89.31% to $93000.0 in 2025, then plunged by 92.47% to $7000.0 in 2026.
- Business Quant data shows XRTX's Income from Non-Controlling Interests at $7000.0 in Q1 2026, $93000.0 in Q4 2025, and $76000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | XORTX Therapeutics | 20.40 Mn | 20.40 Mn | - | 7,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7,000.00 |
| Dec 31, 2025 | 93,000.00 |
| Sep 30, 2025 | 76,000.00 |
| Jun 30, 2025 | -717,700.00 |
| Mar 31, 2025 | 246,000.00 |
| Dec 31, 2024 | 870,349.00 |
| Sep 30, 2024 | 244,000.00 |
| Jun 30, 2024 | 170,066.00 |
| Mar 31, 2024 | -1.72 Mn |
| Dec 31, 2023 | 8.50 Mn |
| Sep 30, 2023 | -1.33 Mn |
| Jun 30, 2023 | -1.69 Mn |
| Mar 31, 2023 | -1.83 Mn |
| Dec 31, 2022 | 1.58 Mn |
| Sep 30, 2022 | 362,947.00 |
| Jun 30, 2022 | 1.13 Mn |
| Mar 31, 2022 | 325,412.29 |
| Dec 31, 2021 | 9.44 Mn |
| Sep 30, 2021 | -6.30 Mn |
| Jun 30, 2021 | 532,860.29 |